Synthesis of Novel Halogenated Heterocycles Based on o-Phenylenediamine and Their Interactions with the Catalytic Subunit of Protein Kinase CK2 by Winiewska-Szajewska, Maria et al.
molecules
Article
Synthesis of Novel Halogenated Heterocycles Based on
o-Phenylenediamine and Their Interactions with the Catalytic
Subunit of Protein Kinase CK2
Maria Winiewska-Szajewska , Agnieszka Monika Maciejewska , Elżbieta Speina , Jarosław Poznański *
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Abstract: Protein kinase CK2 is a highly pleiotropic protein kinase capable of phosphorylating
hundreds of protein substrates. It is involved in numerous cellular functions, including cell viability,
apoptosis, cell proliferation and survival, angiogenesis, or ER-stress response. As CK2 activity is
found perturbed in many pathological states, including cancers, it becomes an attractive target for
the pharma. A large number of low-mass ATP-competitive inhibitors have already been developed,
the majority of them halogenated. We tested the binding of six series of halogenated heterocyclic
ligands derived from the commercially available 4,5-dihalo-benzene-1,2-diamines. These ligand
series were selected to enable the separation of the scaffold effect from the hydrophobic interactions
attributed directly to the presence of halogen atoms. In silico molecular docking was initially applied
to test the capability of each ligand for binding at the ATP-binding site of CK2. HPLC-derived ligand
hydrophobicity data are compared with the binding affinity assessed by low-volume differential
scanning fluorimetry (nanoDSF). We identified three promising ligand scaffolds, two of which have
not yet been described as CK2 inhibitors but may lead to potent CK2 kinase inhibitors. The inhibitory
activity against CK2α and toxicity against four reference cell lines have been determined for eight
compounds identified as the most promising in nanoDSF assay.
Keywords: kinase CK2; differential scanning fluorimetry; molecular modeling; halogenated
heterocycles; hydrophobic contribution; ligand binding; inhibitory activity; cell toxicity
1. Introduction
Protein kinase CK2 is considered as one of the essential human proteins, which is
involved in numerous cellular processes. This is a highly pleiotropic kinase, which can
phosphorylate hundreds of protein substrates including transcriptional factors, proteins
affecting the structure of DNA/ RNA, and/or involved in RNA synthesis and translation,
signaling proteins and also pathogenic virus replication machinery proteins [1]. The nu-
merous natural substrates of kinase CK2 make it indispensable for many cellular functions
including cell viability, apoptosis, cell proliferation and survival, angiogenesis, DNA dam-
age and repair, the ER-stress response, the regulation of carbohydrate metabolism, and in
the nervous system [2]. Kinase CK2 is the holoenzyme that acts in vivo as a heterotetramer,
consisting of two catalytic (α- and/or α’) and two regulatory (β) subunits, but also may act
as a monomeric kinase alone, the regulatory subunit only improving the activity [3].
Since kinase CK2 was found to be overexpressed in many forms of human cancers [4],
its role in cancer pathogenesis is thoroughly investigated. CK2 could promote cell survival
by phosphorylation of sites adjacent to caspase cleavage sites, which blocks its activity [4–7].
Kinase CK2 is also involved in DNA damage response and DNA repair pathways, which
may additionally contribute to the regulation of cancer cell survival [8]. Despite the fact
that the exact function of hCK2 in oncogenesis remains unknown and also its contribution
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may be different among various carcinomas [9–11], widespread interest has been expressed
in targeting this kinase therapeutically [12].
Dozens of kinase CK2 inhibitors have been already described. Among them, ATP-
competitive inhibitors, halogenated benzotriazole, and benzimidazole derivatives play
an important role. Following 5,6-dichloro-1-(β-D-ribofuranosyl)benzimidazole (DRB) [13],
4,5,6,7-tetrabromo-1H-benzotriazole (TBBt) and 4,5,6,7-tetrabromo-1H-benzimidazole (TBBz)
were identified as strong and selective kinase CK2 inhibitors [14]. Further studies on these
compounds resulted in the synthesis of numerous potent kinase CK2 inhibitors, includ-
ing 4,5,6,7-tetrabromo-2-(dimethylamino)benzimidazole (DMAT) [15]. Besides, studies
also showed that derivatives of 4,5,6,7-tetraiodo-1H-benzimidazole (TIBz) inhibit α and α′
subunits of CK2 much more than TBBz does [16]. Sulfurated derivatives of TBBz are also ef-
ficient kinase CK2 inhibitors, e.g., 4,5,6,7-tetrabromo-1H-benzoimidazole-2(3H)-thione (K22)
and 4,5,6,7-tetrabromo-2-(methylthio)-1H- benzoimidazole (K37) inhibit kinase stronger
than TBBt [17,18]. 5,6,7,8-tetrabromo-1-methyl-2,3-dihydro-1H-benzoimidazo[1,2-a] imida-
zole (K44), containing an additional imidazolidine ring in its structure, was also reported to
strongly inhibit CK2 [17,18]. Structures of all these CK2 inhibitors are shown in Figure 1.
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The majority of halogenated ligands target the ATP-binding site of a protein kinase;
however, their poses differ significantly [19–23]. Recent studies have indicated that the
binding mode of halogenated benzotriazoles and benzimidazoles is generally driven by a
competition between a hydrogen bond or salt bridge and halogen bonding [20], while ligand
hydrophobicity contributes significantly to the binding affinity [23,24]. Systematic structural
studies on complexes of halogenated ligands pointed the preferred geometry [25–27] and
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topology [21,28] of a halogen bond in protein-ligand systems, however, the thermodynamic
contribution of a halogen bond to free energy of ligand binding remains debatable, being
estimated in the range of 0.2 [29] to 5 kcal/mol [30].
Our long-term systematic studies on protein kinase CK2 ligands have demonstrated
that halogenated benzotriazole derivatives showed moderate inhibitory activity against
CK2, which is closely related to the physicochemical properties of the ligand [31–36]. We
have also analyzed the effect of substitution pattern, demonstrating that benzotriazole
derivatives carrying halogen atoms at positions 5 and 6 interact with CK2 much stronger
than those substituted at positions proximal to the triazole ring (positions 4 and 7) [34,35].
What is more, the presence of the iodine atom in the structure significantly enhances
the affinity [37], which is in line with results obtained by Janeczko et al. for massively
iodinated benzimidazole derivatives [16]. Both benzotriazoles and benzimidazoles possess
o-phenylenediamine fragment in their structure (see Figure 1). Looking for the novel
groups of compounds as putative kinase CK2 inhibitors, we decided to synthesize groups
of similar compounds, based on o-phenylenediamine configuration.
Here, we synthesized and described six series of heterocyclic halogenated ligands
derived from 4,5-dihalogeno-benzene-1,2-diamines. These ligands were selected to enable
the separation of the scaffold effect from the hydrophobic interactions attributed directly
to the halogen atoms. We measured the hydrophobicity using reverse-phase HPLC. The
binding affinities to the catalytic subunit of human protein kinase CK2 (hCK2α) were
initially assessed using low-volume differential scanning fluorimetry (nanoDSF), and
the dominating modes of binding were analyzed using a molecular modeling approach.
Cytotoxicity against four reference cell lines was tested for the most promising compounds
along with their inhibitory activity against CK2.
2. Results
2.1. Chemistry
We synthesized six series of halogenated heterocyclic compounds starting from 4,5-
dihalogenobenzene-1,2-diamines (1a–e). While the fluorinated, chlorinated, and bromi-
nated amines are commercially available, 4,5-diiodobenzene-1,2-diamine was synthesized,
according to the protocol described previously, using a two-step procedure starting from 1,2-
dinitrobenzene [37]. 2,1,3-Benzothiadiazole derivatives (2a–e) were synthesized from the
corresponding diamines during reaction with thionyl chloride and triethylamine performed
in dichloromethane [38]. 2-Trifluoromethyl-1H-benzimidazole derivatives (3a–e) were syn-
thesized by heating corresponding amine 1a–e in trifluoroacetic acid in the presence of
the catalytic amount of conc. HCl [39]. 2-hydroxymethyl-1H-benzimidazole derivatives
(4a,c–e) were obtained by heating diamine with 2-hydroxyacetic acid in hydrogen chloride
solution [40]. 1H-benzo[d]imidazol-2(3H)-ones (5a,c–e) were synthesized from 1a–e and
N,N′-carbonyldiimidazole (CDI) mixed in DMF [41]. Quinoxaline derivatives (6a,c–e) were
obtained by heating substrate 1a–e with glyoxal solution in ethanol. Quinoxaline-2,3-diol
derivatives (7a–e) were obtained by heating diamine 1a–e with oxalic acid in DMF. The
synthesis strategy of compounds 2–7 is summarized in Scheme 1.
2.2. Hydrophobicity Data
RP-HPLC method, a fast and efficient alternative for standard logD determination
in octan-1-ol/water system [42], was used to assess the hydrophobicity of all synthesized
compounds. This method has been successfully used in our laboratory for halogenated
benzotriazole derivatives, including the evaluation of the effect of hydrophobicity on their
binding to the catalytic subunit of protein kinase CK2 [24,43].
As expected, the substitution of two hydrogen atoms with the larger halogen atoms:
fluorine, chlorine, bromine, or iodine, respectively, always results in an increase of apparent
hydrophobicity (Figure 2A). This trend is generally independent on the scaffold of the
molecule (Figure 2B).
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Figure 2. Effect of substitution at the two distant positions of the benzene ring with a halogen atom
on HPLC-derived hydrophobicity index (log(τ)) (A). The same values are represented relative to the
unsubstituted compound of the same scaffold (B).
Indeed, regardless of the scaffold, the increase of hydrophobicity upon halogen sub-
stitution in distant positions of the benzene ring of 2-trifluoromethyl- 1H- benzimidazole
(3a), 2-hydroxymethyl-1H-benzimidazole (4a), and 1H-benzo[d]imidazol-2(3H)-one (5a) is
identical. A similar trend is also observed in the case of quinoxaline-2,3-diol (7a) and benzo-
1,2-diamine (1a), however, for the latter, the effect of halogenation is shifted downwards by
0.1 log(τ) units. The largest changes in hydrophobicity experience quinoxaline (6a) deriva-
tives, which should be directly attributed to the lack of the effect of electronegative halogen
atom on the proximal proton-donating groups. Such effect, partially compensating halogen
hydrophobicity, was evidenced in protein-ligand structures, in which hydrogen bonds
proximal to a halogen atom were statistically shortened (so must be regarded as stronger)
when a nitrogen atom close to the halogen atom (less than six chemical bonds) was a
hydrogen bond donor [44]. No su h configuration i present in 6a, so the effect of halogen
substitution is larger because it cannot be compensated in 6c–e by the halog -induced
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strengthening of solute-solvent interaction. Finally, the effect of halogen substitution in the
most hydrophobic 2,1,3-benzothiadiazole (2a) remains irregular, which putatively results
from an uncontrolled aggregation of these solutes.
2.3. Binding Affinity—Thermal Shift Assay
Binding affinities of the newly synthesized compounds towards hCK2α were assessed
with the low-volume differential scanning fluorimetry (nanoDSF). The shift of the tempera-
ture of thermal denaturation in the presence of 10-fold excess of a particular ligand relative
to the apo form of hCK2α (∆Tm) can be used as a semi-qualitative measure of the binding
affinity [35] or inhibitory activity [45].
Groups of ligands with different scaffolds vary visibly in their affinity to the target
protein (see Table 1 and Figure 3). Interestingly, two of the most hydrophobic groups
of compounds, 2,1,3-benzothiadiazoles (2a–e) and quinoxalines (6a–e), virtually do not
interact with hCK2α—for all these compounds, ∆Tm value never exceeds 1 ◦C. Benzene-
1,2-diamine derivatives (1a–e) also interact weakly with hCK2α (∆Tm value 1.7 ◦C for
1e), but this effect should be attributed directly to the size of the ligand—the absence
of the second aromatic ring in the scaffold that appears to be necessary for the efficient
ligand-binding to the kinase [20]. There is no general correlation between hydrophobicity
and binding affinity, however, when one analyzes individual series representing the same
scaffold. A comparison of log(τ) and ∆Tm for the protein–ligand complexes indicates that
any increase in ligand hydrophobicity is clearly reflected by an increase in binding affinity,
as long as the ligand binds to the target (see Figure 3). Moreover, it seems that the effect
of Cl, Br, and I substitution on the stabilization of the protein–ligand complexes not only
does not depend on the structure of the heterocyclic ring but is directly proportional to the
hydrophobicity of the halogen. The latter is evidenced by almost parallel lines representing
the contribution of halogen atoms in individual ligands. It could be thus anticipated that for
the studied series of ligands, the thermodynamic contribution of non-specific hydrophobic
interactions of halogen atoms to the free energy of ligand binding remains separated from
that of the direct electrostatic interactions involving a more polar heterocyclic ring. This
hypothesis was tested with in silico modeling of protein–ligand structures.
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Figure 3. Correlation between HPLC-derived hydrophobicity index (log(τ)) and the ∆Tm determined
using nanoDSF.
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Table 1. NanoDSF-derived ∆Tm, HPLC-derived hydrophobicity index log(τ) values and retention times Tret of tested
compounds, and Gibbs free energy of binding adopted from the docking scores.
Entry Structure R Compound ∆Tm [◦C] Tret [min] log(τ) ∆Gbind [kJ/mol]
1
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2.4. Inhibitory Activity
Since in the thermal shift assay, most of the studied compounds seem to have a
negligible affinity towards hCK2α, only eight compounds were further subjected to the
direct measurement of IC50—solely compounds with the thermal shift above 2 ◦C may be
considered as at least moderate inhibitors of hCK2α.
Comparison of thermal shift assay data (∆Tm) with the directly measured IC50 con-
firms that nanoDSF is an attractive method for inhibitors screening, however, for ligands
with different scaffolds, hence different modes of binding, this might not be directly re-
flected in the biochemical assay.
Finally, it should be mentioned that the inhibitory activity of two compounds found
the most promising according to nanoDSF (i.e., 5,6-diiodo-2-trifluoromethyl-1H- benz-
imidazole, 3e, and 6,7-diiodooquinoxaline-1,3-diol,7e) also exhibit the highest inhibitory
activity with micromolar IC50 values (see Table 2).
2.5. Cell Toxicity
The same four bromo and four iodo- derivatives that, according to nanoDSF assay,
interact with the catalytic subunit of CK2α (scaffolds 3, 4, 5, 7) were tested against the reference
cancer cell lines: epidermoid carcinoma A-431, colorectal carcinoma HCT116, HCT116p53−/−,
and normal fibroblasts BJ. All of them displayed moderate activity to reduce cell viability
(<100 µM). Interestingly, compound 3e was identified as even more active than 3d, the
promising activity of which has been already r ported [46]. In this study compound, 3d
displayed IC80 values between 2 and 29.1 µM tested for five cancer cell lines (IM-9, MOLT3,
U-937, MCF-7, and PC-3), and 8.7 µM on phytohemagglutinin-stimulated normal human
lymphocytes. It was especially active against two cell lines: MCF-7 (breast carcinoma) and
PC-3 (prostate carcinoma), with IC80 values below 3 µM. Our data show the selectivity index
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of 3e ~10 (relative to BJ fibroblasts), which makes this compound worth further investigations.
We were unable to determine the cytotoxicity for 5e, for which the observed nonmonotonic
dose-response effect was most probably caused by uncontrolled aggregation. All cell toxicity
data are summarized in Table 2, and the analyses of viability are shown in Supplementary
Figures S30–S37. The toxicity is generally uncorrelated with the inhibitory activity; however,
this effect can be directly assigned to membrane permeability. This hypothesis is strongly
supported by a clear correlation between compound hydrophobicity (log (τ)) and IC50 values
estimated from viability data (Figure 4).
Table 2. Activity of bromo (d) and iodo (e) derivatives against hCK2α and four human cell lines.
Compound
IC50 [µM]
hCK2α Assay A-431 BJ HTC116 HCT116p53−/−
3d 15 ± 3 13 ± 2 55 ± 6 10 ± 2 12 ± 2
3e 7 ± 4 7 ± 1 55 ± 5 6 ± 1 6 ± 1
4d >1000 45 ± 5 145 ± 15 21 ± 1 28 ± 3
4e 25 ± 5 39 ± 10 15 ± 2 20 ± 2 23 ± 2
5d >1000 180 ± 40 40 ± 5 18 ± 3 22 ± 3
5e 13 ± 2 - - - -
7d 13 ± 4 385 ± 82 16 ± 2 195 ± 35 850 ± 300
7e 2 ± 1 94 ± 14 128 ± 13 41 ± 4 70 ± 10
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Interaction between a fluorinated ligand (1b, 2b, 3b, 7b) and the protein is found 
generally overestimated (Figure 5, red points). Contrarily, the binding affinity of the ma-
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Interestingly, contrary to the enzymatic assay, the activity of 7e remains marginal
(IC50 ~100 µM), but such a low value should be assigned to a moderate hydrophobicity
of this compound. In this context, one can expect that esterification of the two hydroxyl
groups of 7e would improve its apparent activity in viability tests.
2.6. Molecular Modeling
Molecular modeling was initially performed to assess whether a given scaffold could
be harbored at the ATP binding site. Free energy of ligand binding (∆Gbind) was estimated
with the aid of the VINA-AutoDock algorithm implemented in Yasara Structure [47]. The
obtained ensembles of structures agreed qualitatively with our knowledge concerning
the binding of halogenated ligands at the ATP-binding site of CK2α [21,48,49]. Thus,
all chlorinated, brominated, and iodinated ligands preferably adopt the orientation, in
which both halogen atoms are solvent-protected, being close to the hinge region, while
the heterocyclic ring points towards the polar region of the ATP-binding site formed
by sidechains of Lys68, Glu81, and Asp175. The competition between hydrophobic and
electrostatic interactions is visible for the majority of tested ligands, again clearly identifying
the balance of hydrophobic and electrostatic interactions as the main driving force.
Interaction between a fluorinated ligand (1b, 2b, 3b, 7b) and the protein is found
generally overestimated (Figure 5, red points). Contrarily, the binding affinity of the
majority of iodinated and some brominated ligands is underestimated (Figure 5, blue and
green points). However, the latter effect may reflect the absence of the parameterization of
halogen bonding interactions in the classical force-field used in the scoring function [50].
On the other hand, these discrepancies can be treated as indicators for the existence of
halogen bonding in these complexes, which mainly applies to 3e, 4e, and 7e. Interestingly,
despite the discrepancy in the estimated binding affinity, most of the low-energy poses of
5,6-diiodo-, 5,6-dibromo, and 5,6-dichloro- derivatives preserve halogen atoms pointing
toward the hinge region, thus, in the orientation, enabling halogen-bonding, with the
heterocyclic ring close to Lys68 (see Supplementary Table S1 and Figures S40 and S41).
Molecules 2021, 26, 3163 10 of 18 
 
 
with the heterocyclic ring close to Lys68 (see Supplementary Table S1 and Figures S40 and 
S41). 
 
Figure 5. Correlation between the calculated Gibbs free energy of binding of synthesized com-
pounds to CK2 obtained from molecular modeling (ΔGbind) and the ΔTm, estimated with the aid of 
nanoDSF. 
3. Discussion 
We have synthesized six groups of halogenated heterocycles, based on benzene-1,2,-
diamine derivatives. To analyze their applicability as the precursors of potential hCK2 
inhibitors, we used molecular modeling together with the nanoDSF method, which ena-
bled qualitative comparison of their binding affinity. Many studies have been carried out 
on CK2 Type I inhibitors and some preferences of ligands in CK2 ATP-binding sites are 
already well known [20,33,35,48,51]. Besides the obvious steric hindrance of the scaffold, 
the two main driving forces of binding ligand at the ATP- binding site of CK2α are clearly 
identified: the electrostatic contribution together with hydrophobic effect [20,33,35]. Neg-
atively charged ligands commonly bind deeper in the CK2α pocket, preferably interacting 
with Lys68 [20]. Additionally, the substitution with hydrophobic halogen atoms signifi-
cantly increases the affinity towards the CK2α by a favorable change in the physico-chem-
ical properties of the ligand. The latter also includes the possible formation of halogen 
bonds with the hinge region [48]. 
Using these different groups of compounds, we analyzed the interplay between the 
scaffold and the effect of substitution with halogen atoms. For smaller scaffolds, like ben-
zotriazole/benzimidazole, unsubstituted on triazole/imidazole ring, a salt bridge or hy-
drogen bond formation with Lys68 and halogen bonding with the hinge region are largely 
Figure 5. Correlation between the calculated Gibbs free energy of binding of synthesized compounds
to CK2 obtained from molecular modeling (∆Gbind) and the ∆Tm, estimated with the aid of nanoDSF.
Molecules 2021, 26, 3163 9 of 16
3. Discussion
We have synthesized six groups of halogenated heterocycles, based on benzene-1,2,-
diamine derivatives. To analyze their applicability as the precursors of potential hCK2
inhibitors, we used molecular modeling together with the nanoDSF method, which enabled
qualitative comparison of their binding affinity. Many studies have been carried out on CK2
Type I inhibitors and some preferences of ligands in CK2 ATP-binding sites are already well
known [20,33,35,48,51]. Besides the obvious steric hindrance of the scaffold, the two main
driving forces of binding ligand at the ATP- binding site of CK2α are clearly identified: the
electrostatic contribution together with hydrophobic effect [20,33,35]. Negatively charged
ligands commonly bind deeper in the CK2α pocket, preferably interacting with Lys68 [20].
Additionally, the substitution with hydrophobic halogen atoms significantly increases the
affinity towards the CK2α by a favorable change in the physico-chemical properties of the
ligand. The latter also includes the possible formation of halogen bonds with the hinge
region [48].
Using these different groups of compounds, we analyzed the interplay between the
scaffold and the effect of substitution with halogen atoms. For smaller scaffolds, like
benzotriazole/benzimidazole, unsubstituted on triazole/imidazole ring, a salt bridge or
hydrogen bond formation with Lys68 and halogen bonding with the hinge region are largely
mutually exclusive because these two regions are in the hCK2α, too far apart for these
interactions to occur simultaneously [20,48]. This is why we tested larger scaffolds with
either a larger heterocyclic ring (6a–e, 7a–e) or substitution in the imidazole, both of them to
preserve possible interactions with a hinge. We analyzed solely dihalogenated compounds
of the same pattern of halogen atoms at the benzene ring to assure that predominating
interactions with the hinge region (occurring with more halogen atoms) and configuration
effect (depending on the halogenation pattern) will not predominate or interfere with
the interdependence we were analyzing [24,34,43]. Interestingly, for the tested halogen
configuration, we can notice that only ligands with uneven charge distribution on the
non-benzene ring (groups 3, 4, 5, 7) exhibit measurable affinity towards CK2, while ligands
even much hydrophobic but without proton-donating groups (series 2 and 6) do not
stabilize the complex (i.e., ∆Tm < 1 ◦C). This observation indicates that two halogen atoms
are insufficient to stabilize the ligand in the complex with a position close to the linker
region, and the formation of hydrogen bonds with the lysine seems to be necessary. Such
dependence of ligand position on the number of halogen atoms was observed for the
halogenated benzotriazoles, where 5,6 dibromobenzotriazole interacts with Lys68 (pdb
6TLP), while tetrabromobenzotriazole interacts either with the hinge region or with Lys68
(pdb 6TLL). What is more, an inspection of in silico determined structures for complexes
with ligands that bind to the protein (∆Tm < 1 ◦C) points out to this unique interplay, as
ligands with no halogen atom or with fluorine (which is not capable for the formation of
halogen bond [52]) display in almost all cases different orientation relative to the hinge
region (see Figures S40 and S41), possibly forming hydrogen bonds. The substitution with
other halogen atoms switches the preferable orientation of the ligand, which has an effect
that is somehow explicable by hydrophobic interactions. However, since the force-field
used in the docking procedure does not include the explicit potential for a halogen bond,
these interactions are underestimated.
These different orientations of chlorinated, brominated, and iodinated compounds
might explain why the relation of measured log(τ) and ∆Tm values for series represent-
ing the same compound scaffold is linear solely for these three substituents, but not for
hydrogen and fluorine (see Figure 3).
Six out of eight compounds with the highest shift in nanoDSF assay displayed at least
moderate inhibitory activity in the enzymatic assay; among them, 3e and 7e were the most
active in both experiments. Some of tested scaffolds have already been reported in the liter-
ature. Thus, 1H-benzo[d]imidazol-2(3H)-one derivatives (5a–d) moderately interact with
CK2 (∆Tm values are up to 2.4 ◦C for iodinated derivative with and IC50 = 13± 2 µM, while
4,5,6,7-tetrabromo-1H-benzo[d]imidazol-2(3H)-one inhibits CK2 stronger (IC50 = 0.39 µM
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and Ki = 0.20 µM) [15]. 2-Trifluoromethyl-1H-benzimidazole derivatives have been also
reported: compound 3d with IC50 value against CK2 of 28 µM (being in line with mea-
surement by us, 15 ± 3 µM) and 4,5,6-tribrominated and tetrabrominated analogs with the
inhibitory activity of 1.2 µM and 0.6 µM, respectively [53]. Replacement of bromine atoms
with iodine additionally improves the activity up to 0.12 µM [54].
It is worth noting that for these two 5,6-halogenated scaffolds, the observed tendency
is opposite to that observed for their tetrahalogenated analogs. Thus, 2-trifluoromethyl-
1H-benzimidazole interacts stronger than the 1H-benzo[d]imidazol-2(3H)-one counterpart
(7 vs. 13 µM). This again points out the subtle interplay between the scaffold and the
substitution with halogen atoms, indicating that the interaction of 2-trifluoromethyl-1H-
benzimidazole with Lys68 is slightly stronger than for its isostructural analog-carrying
carbonyl group.
In this context, quinoxaline-2,3-diol derivatives (7d,e) might lead to novel potent
CK2 inhibitors, as both inhibit hCK2α comparable to 2-trifluoromethyl-1H-benzimidazole
derivatives (3d,e), stabilizing the complex for approx. 4 ◦C (IC50 = 13 and 2 vs. 15 and
7 µM, respectively), but have not been reported as kinase CK2 inhibitors yet.
Finally, the viability tests performed for reference cell lines showed moderate activity
for some compounds. Interestingly, IC50 values determined in this test are correlated with
a compound’s hydrophobicity rather than the inhibitory activity in the CK2α assay. This
indicates a dominant role of membrane permeability, but it may also indicate that CK2α is
not a major target for studied test compounds.
4. Materials and Methods
4.1. Chemistry
All starting materials and solvents for reactions were purchased from Sigma Aldrich
(now Merck KGaA, Darmstadt, Germany), Fluorochem (Hadfield, UK), ABCR (Karlsruhe,
Germany), or Chempur (Piekary Śląskie, Poland). 1H-NMR spectra were recorded with
Varian 500 MHz spectrometer. TMS or the residual solvent signal were used as the internal
standard. High-resolution mass spectrometry spectra were recorded on a TQ OrbitrapVelos
instrument (Thermo Scientific, Waltham, MA, USA). The reaction progress was monitored
by the thin-layer chromatography analysis using silica gel plates (Kieselgel 60F254. Merck,
Darmstadt, Germany). Column chromatography was performed on Silica Gel 60 (0.040–
0.063 mm. Merck, Darmstadt, Germany).
Detailed experimental data, as well as spectral data for all synthesized compounds,
are available in the Supplementary Materials.
Synthesis of 2,1,3-benzothiadiazole derivatives (2a–e)
Benzene-1,2-diamine derivative (5 mmol) was dissolved in dry DCM (15 mL). Triethylamine
(3 mL) was added, then thionyl chloride (15 mmol, 1.1 mL) dissolved in 3 mL of dry DCM
was added dropwise at 0 ◦C. The reaction mixture was allowed to reach room temperature,
then it was heated at 40 ◦C overnight. Afterward, the reaction mixture was filtered. The
filtrate was evaporated, the crude product was purified by column chromatography on
silica gel using DCM as eluent.
2,1,3-benzothiadiazole (2a) Yield = 66%. 1H-NMR (400 MHz, d-DMSO) δ 7.62–7.72 (2H,
m, ArH), 7.99–8.80 (2H, m, ArH); 13C-NMR (100 MHz, d-DMSO) δ 121.24, 129.83, 154.19;
HRMS calcd. for C6H5N2S [M + H]+: 137.01680, found: 137.01673.
5,6-difluoro-2,1,3-benzothiadiazole (2b) Yield = 66%. 1H-NMR (500 MHz, d-DMSO) δ
8.18–8.27 (2H, m, ArH); 13C-NMR (125 MHz, d-DMSO) δ 106.37, 106.54, 150.46, 1651.77,
151.94, 153.81, 153.97; HRMS calcd. for C6H3F2N2S [M + H]+: 172.99795, found: 172.99803.
5,6-dichloro-2,1,3-benzothiadiazole (2c) Yield = 75%. 1H-NMR (500 MHz, d-DMSO) δ 8.53
(2H, s, ArH); 13C-NMR (125 MHz, d-DMSO) δ 121.75, 133.54, 152.61; HRMS calcd. for
C6H3Cl2N2S [M + H]+: 204.93885, found: 204.93872.
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5,6-dibromo-2,1,3-benzothiadiazole (2d) Yield = 78%. 1H-NMR (500 MHz, d-DMSO) δ 8.67
(2H, s, ArH); 13C-NMR (125 MHz, d-DMSO) δ 124.95, 126.26, 153.32; HRMS calcd. for
C6H3Br2N2S [M + H]+: 292.83782, found: 292.83741.
5,6-diiodo-2,1,3-benzothiadiazole (2e) Yield = 47%. 1H-NMR (500 MHz, d-DMSO) δ 8.79
(2H, s, ArH); 13C-NMR (125 MHz, d-DMSO) δ 111.39, 130.38, 154.22; HRMS calcd. for
C6H3I2N2S [M + H]+: 388.81008, found: 388.30973.
Synthesis of 2-trifluoromethylo-1H-benzimidazole derivatives (3a–e)
Benzene-1,2-diamine derivative (2 mmol) was dissolved in trifluoroacetic acid (2 mL) and
a catalytic amount of concentrated HCl was added. The reaction mixture was heated at
reflux overnight. The reaction was quenched by the addition of 50 mL of concentrated
NaHCO3 solution; afterwards, it was extracted by ethyl acetate (3 × 30 mL). Combined
organic layers were dried by MgSO4, then the solvent was evaporated. The crude product
was purified by column chromatography on silica gel using 85:15 (hexane:AcOEt) as eluent
(compounds 3d and 3e) or by recrystallization from hexane (compounds 3a, 3b, and 3c).
2-trifluoromethylo-1H-benzimidazole (3a) Yield = 73%. 1H-NMR (500 MHz, d-DMSO) δ
7.34–7.42(2H, m, ArH), 7.68-7.77(2H, m, ArH); 13C-NMR (125 MHz, d-DMSO) δ 115.88,
118.02, 120.17, 122.32, 124.09, 139.90, 140.22; HRMS calcd. for C8H6F3N2 [M + H]+:
187.04776, found: 187.04773.
5,6-difluoro-2-trifluoromethylo-1H-benzimidazole (3b) Yield = 67%. 1H-NMR (500 MHz,
d-DMSO) δ 7.71–7.85 (2H, m, ArH); HRMS calcd. for C8H4F5N2 [M + H]+: 223.02892,
found: 223.02882.
5,6-dichlorlo-2-trifluoromethylo-1H-benzimidazole (3c) Yield = 85%. 1H-NMR (500 MHz,
d-DMSO) δ 8.00 (2H, s, ArH); HRMS calcd. for C8H4F3Cl2N2 [M + H]+: 254.96981,
found: 254.96976.
5,6-dibromo-2-trifluoromethylo-1H-benzimidazole (3d) Yield = 40%. 1H-NMR (500 MHz,
d-DMSO) δ 8.16 (2H, s, ArH); 13C-NMR (125 MHz, d-DMSO) δ 115.88; HRMS calcd. for
C8H4F3Br2N2 [M + H]+: 342.86878, found: 342.86896.
5,6-diiodo-2-trifluoromethylo-1H-benzimidazole (3e) Yield = 33%. 1H-NMR (500 MHz,
d-DMSO) δ 8.32 (2H, m, ArH); HRMS calcd. for C8H4F3I2N2 [M + H]+: 438.84105,
found: 438.84123.
Synthesis of 2-hydroxymethylo-1H-benzimidazole derivatives (4a,c–e)
Benzene-1,2-diamine derivative (5 mmol) and hydroxyacetic acid (15 mmol, 1.14 g) were
dissolved in water (1.5 mL) and concentrated HCl (0.5 mL) was added. The reaction
mixture was heated at reflux overnight. The reaction was cooled to RT and then 20% NaOH
solution was added until pH = 13. The formed participate was filtered and washed several
times with water. Compound 4e was additionally purified by recrystallization from MeOH.
2-hydroxymethylo-1H-benzimidazole (4a) Yield = 85%. 1H-NMR (500 MHz, d-DMSO) δ
4.70 (2H, s, CH2), 5.69 (1H, s br, OH), 7.11-7.15 (2H, m, ArH), 7.49 (2H, s br, ArH), 12.30
(1H, s br, NH); 13C-NMR (125 MHz, d-DMSO) δ 57.74, 121.25, 155.02; HRMS calcd. for
C8H9N2O [M + H]+: 149.07094, found: 149.07089.
5,6-dichloro-2-hydroxymethylo-1H-benzimidazole (4c) Yield = 84%. 1H-NMR (500 MHz,
d-DMSO) δ 4.70 (2H, s, CH2), 5.81 (1H, s br, OH), 7.73 (2H, s br, ArH), 12.04 (1H, s br,
NH); 13C-NMR (125 MHz, d-DMSO) δ 57.57, 123.71, 158.10; HRMS calcd. for C8H7Cl2N2O
[M + H]+: 216.99299, found: 216.99308.
5,6-dibromo-2-hydroxymethylo-1H-benzimidazole (4d) Yield = 81%. 1H-NMR (500 MHz,
d-DMSO) δ 4.70 (2H, s, CH2), 5.83 (1H, s br, OH), 7.88 (2H, s br, ArH); 13C-NMR (125 MHz, d-
DMSO) δ 57.50, 115.47, 119.18, 157.91; HRMS calcd. for C8H7Br2N2O [M + H]+: 304.89196,
found: 304.89222.
5,6-diiodo-2-hydroxymethylo-1H-benzimidazole (4e) Yield = 66%. 1H-NMR (500 MHz,
d-DMSO) δ 4.68 (2H, s, CH2), 5.80 (1H, s br, OH), 8.07 (2H, s br, ArH), 12.52 (1H, s br,
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NH); 13C-NMR (125 MHz, d-DMSO) δ 57.48, 98.13, 157.17; HRMS calcd. for C8H7I2N2O
[M + H]+: 400.86423, found: 400.86446.
Synthesis of 1H-benzo[d]imidazol-2(3H)-one derivatives (5a,c–e)
Benzene-1,2-diamine derivative (3 mmol) and N,N′-carbonyldiimidazole (CDI) (3 mmol,
486 mg) were mixed in DMF (4 mL) overnight at RT. The reaction was quenched by the
addition of water (20 mL). The formed participate was filtered and washed several times
with water. Compound 5d was additionally purified by recrystallization from ethyl acetate,
then MeOH.
1H-benzo[d]imidazol-2(3H)-one (5a) Yield = 45%. 1H-NMR (500 MHz, d-DMSO) δ 6.91
(4H, s br, ArH), 10.56 (2H, s br, NH); 13C-NMR (125 MHz, d-DMSO) δ 108.46, 120.40, 129.65,
155.25; HRMS calcd. for C7H7N2O [M + H]+: 135.05529, found: 135.05526.
5,6-dichloro-1H-benzo[d]imidazol-2(3H)-one (5c) Yield = 67%. 1H-NMR (500 MHz, d-
DMSO) δ 7.08 (2H, s br, ArH), 10.91 (2H, s br, NH); 13C-NMR (100 MHz, d-DMSO)
δ 109.73, 122.35, 129.83, 155.18; HRMS calcd. for C7H5Cl2N2O [M + H]+: 202.97734,
found: 202.97743.
5,6-dibromo-1H-benzo[d]imidazol-2(3H)-one (5d) Yield = 67%. 1H-NMR (500 MHz, d-
DMSO) δ 7.20 (2H, s br, ArH), 10.90 (2H, s br, NH); 13C-NMR (100 MHz, d-DMSO)
δ 112.66, 113.88, 130.63, 154.93; HRMS calcd. for C7H5Br2N2O [M + H]+: 290.87631,
found: 290.87626.
5,6-diiodo-1H-benzo[d]imidazol-2(3H)-one (5e) Yield = 67%. 1H-NMR (500 MHz, d-DMSO)
δ 7.41 (2H, s br, ArH), 10.80 (2H, s br, NH); 13C-NMR (100 MHz, d-DMSO) δ 96.40, 118.00,
131.46, 154.58; HRMS calcd. for C7H5I2N2O [M + H]+: 386.84858, found: 386.84861.
Synthesis of quinoxaline derivatives (6a,c–e)
Benzene-1,2-diamine derivative (3 mmol) and 40% glyoxal solution in water (9 mmol,
1.3 mL) were heated at reflux in EtOH (6 mL) overnight. The reaction was quenched by the
addition of water (50 mL). The formed participate was filtered and washed several times
with water (compound 6a was extracted with AcOEt (3 × 30 mL). Compounds 6c and 6d
were purified by recrystallization from MeOH. Compounds 6a and 6e were purified by
column chromatography on silica gel, using 8:2 (hexane:AcOEt) as eluent.
quinoxaline (6a) Yield = 70%. 1H-NMR (500 MHz, d-DMSO) δ 7.84–7.92 (2H, m, ArH),
8.08–8.16 (2H, m, ArH), 8.96 (2H, s br, ArH); 13C-NMR (125 MHz, d-DMSO) δ 129.14, 130.21,
142.23, 145.72; HRMS calcd. for C8H7N2 [M + H]+: 131.06037, found: 131.06042.
6,7-dichloroquinoxaline (6c) Yield = 99%. 1H-NMR (500 MHz, d-DMSO) δ 8.46 (2H, s, ArH),
9.02 (2H, s, ArH); 13C-NMR (125 MHz, d-DMSO) δ 130.13, 133.01, 141.15, 147.13; HRMS
calcd. for C8H5Cl2N2 [M + H]+: 198.98234, found: 198.98252.
6,7-dibromoquinoxaline (6d) Yield = 89%. 1H-NMR (500 MHz, d-DMSO) δ 8.56 (2H, s,
ArH), 9.01 (2H, s, ArH); 13C-NMR (125 MHz, d-DMSO) δ 125.77, 133.31, 141.56, 147.14;
HRMS calcd. for C8H5Br2N2 [M + H]+: 286.88140, found: 286.88165.
6,7-diiodoquinoxaline (6e) Yield = 25%. 1H-NMR (500 MHz, d-DMSO) δ 8.68 (2H, s, ArH),
8.96 (2H, s, ArH); 13C-NMR (125 MHz, d-DMSO) δ 111.06, 138.74, 141.92, 1467.83; HRMS
calcd. for C8H5I2N2 [M + H]+: 382.85366, found: 382.85426.
Synthesis of quinoxaline-2,3-diol derivatives (7a–e)
Benzene-1,2-diamine derivative (3 mmol) and oxalic acid (9 mmol, 810 mg) were heated
at 120 ◦C in DMF (1 mL) overnight. The reaction was quenched by the addition of wa-
ter (20 mL). The formed participate was filtered and washed several times with water
(compound 6a was extracted with AcOEt (3 × 10 mL)). Crude products were purified by
recrystallization from EtOH.
quinoxaline-1,3-diol (7a) Yield = 57%. 1H-NMR (500 MHz, d-DMSO) δ 7.02–7.10 (2H, m,
ArH), 7.10–7.16 (2H, m, ArH), 11.90 (2H, s, 2xOH); 13C-NMR (125 MHz, d-DMSO) δ 115.12,
123.00, 125.60, 155.17; HRMS calcd. for C8H7N2O2 [M + H]+: 163.05020, found: 163.05011.
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6,7-difluoroquinoxaline-1,3-diol (7b) Yield = 68%. 1H-NMR (500 MHz, d-DMSO) δ 7.00–
7.11 (2H, m, ArH), 11.92 (2H, s2xOH); 13C-NMR (125 MHz, d-DMSO) δ 103.63, 103.74,
103.81, 122.26, 122.32, 143.91, 144.04, 145.83, 145.96, 154.70; HRMS calcd. for C8H5F2N2O2
[M + H]+: 199.03136, found: 199.03138.6,7-dichloroquinoxaline-1,3-diol (7c) Yield = 86%.
1H-NMR (500 MHz, d-DMSO) δ 7.21 (2H, s, ArH), 12.00 (2H, s, 2xOH); 13C-NMR (100 MHz,
d-DMSO) δ 115.99, 124.29, 126.03, 154.71; HRMS calcd. for C8H5Cl2N2O2 [M + H]+:
230.97226, found: 230.97218.
6,7-dibromooquinoxaline-1,3-diol (7d) Yield = 91%. 1H-NMR (500 MHz, d-DMSO) δ 7.38
(2H, s, ArH), 11.99 (2H, s, 2xOH); 13C-NMR (100 MHz, d-DMSO) δ 116.15, 118.96, 126.64,
154.73; HRMS calcd. for C8H5Br2N2O2 [M + H]+: 318.87123, found: 318.87105.
6,7-diiodooquinoxaline-1,3-diol (7e) Yield = 63%. 1H-NMR (400 MHz, d-DMSO) δ 7.51
(2H, s, ArH), 11.77 (2H, s br, 2xOH); 13C-NMR (100 MHz, d-DMSO) δ 99.11, 124.80, 128.06,
155.49; HRMS calcd. for C8H5I2N2O2 [M + H]+: 414.84349, found: 414.84366.
4.2. NanoDSF
hCK2α was expressed and purified according to the method described previously [35].
Thermal stability of 1:10 protein–ligand complexes was monitored on Prometheus (Nanotem-
per Technologies, München, Germany) using PR-C002 Prometheus NT.48 Standard Capillaries
using temperature ramp of 20 to 80 ◦C with 1 ◦C/min heating rate. Temperature-induced
variation in ratio fluorescence intensity at 330 and 350 nm was globally analyzed using the
procedure described before [37]. All experiments were performed in 25 mM Tris–HCl (pH 8,
0.5 M NaCl) with 2% (v/v) DMSO. Protein was kept in constant 2.5 µM concentration.
4.3. Inhibitory Activity against Human CK2α
The inhibitory effect of 8 selected compounds was monitored based on the luminescence
measured with the SpectraMax iD3 Multi-Mode Microplate Reader (Molecular Devices, San
Jose, CA, USA), using the previously described method with the aid of ADP-Glo kinase assay
(Promega, Walldorf, Germany) [43]. Inhibitor concentration varied in the range of 1 nM–1 mM
(see Supplementary Figure S38). Each experiment was repeated in triplicate and IC50 values
were further estimated globally using the sigmoidal dose-response equation implemented in
Origin 9.4 package (www.originlab.com, upgraded 20.07.27).
4.4. Cell Viability Assay
The following human cell lines were used in this study: (i) epidermoid carcinoma
A-431 (ATCC® CRL-1555), (ii) colorectal carcinoma HCT116 (ATCC® CCL-247), (iii) col-
orectal carcinoma HCT116p53−/−, and (iv) normal fibroblasts BJ (ATCC® CRL-2522). The
HCT116p53−/− cell line was a kind gift from professor Bert Vogelstein (John Hopkin’s
University, Baltimore, MD, USA). The remaining cell lines were purchased from ATCC
(Manassas, VA, USA) or Sigma Aldrich by Merck (Darmstadt, Germany).
Cells were cultured in Dulbecco’s modified Eagle’s or Roswell Park Memorial Institute
(RPMI)-1640 medium supplemented with 10% or 15% fetal bovine serum (Gibco by Thermo
Fisher Scientific, Waltham, MA, USA) under standard culture conditions (37 ◦C, 5% CO2)
in a humidified incubator with atmospheric oxygen.
The viability of cells was assayed by measuring the conversion of MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to the formazan (the rate of this
reaction is proportional to the number of surviving cells). Cells were seeded in a 96-well
plate at a density of 1500–2500 cells per well, 24 h before treatment. Treatment with tested
compounds and cisplatin (0.25–160 µM) was performed for 72 h. MTT stock solution
(Sigma-Aldrich) was added at the final concentration 0.5 mg/mL. After 2 h of incubation at
37 ◦C, water-insoluble formazan was dissolved in a lysis buffer containing 20% SDS, 50%
DMF, 2.5% hydrochloric acid, and 2.5% acetic acid. Optical densities were measured at
570 nm using a scanning multi-well spectrophotometer (PARADIGM Detection Platform;
Beckman Coulter, Brea, CA, USA).
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4.5. Chromatographic Hydrophobicity Index
Chromatographic hydrophobicity index (log(τ)) was determined with the reverse
phase HPLC (RP-HPLC). Column: Nova-pak® C18 4 µm, 4.6 × 250 mm. Eluent: 2:1
methanol: 20 mM aqueous ammonium formate (pH = 8) (v/v). Flow: 0.7 mL/min. Detector
wavelength: 280 nm. The individual retention times (Tret) were converted to a hydrophobic-
ity scale according to the formula τ = (Tret − T0)/T0. where the retention time of unretained
solvent (T0) was estimated to 300 s [24].
4.6. Molecular Modeling
Docking of all tested ligands at the binding site of the catalytic subunit of human
protein kinase CK2 was performed with VINA algorithm implemented in Yasara Structure
package (www.yasara.com, version 20.12.24) using amber14 force-field with 8 Å cutoff
for long-range electrostatic interactions. We used 8 just-resolved structures of complexes
of hCK2α with variously brominated benzotriazoles (Protein Data Bank records 6TLW,
6TLV, 6TLU, 6TLS, 6TLR, 6TLP, 6TLO, and 6TLL) as the reference protein structures.
This, including alternative protein conformations, stated 18 structures to be tested as the
‘receptor’. Such an extended set of template protein structures was chosen to allow the
sampling of a larger conformational space that allows multiple ligand orientations at the
binding site (see Supplementary Figure S39). In silico screening procedure was restricted to
the cuboid region that contained all residues from the ATP binding site, further additionally
extended by 2 Å in each direction. During simulations, the sidechain atoms of protein
residues proximal to the location of the original ligand (4 Å threshold) were flexible, while
coordinates of all other protein atoms were kept fixed. Finally, each of 35 ligands was
subjected to 25 independent cycles of the docking procedure using 18 structural templates.
The resulting structures were then clustered, and for each ligand, the highest scored one
was used as the representative. This score was used as a rough estimate of the free energy
of ligand binding.
Supplementary Materials: The following are available online. Figures S1–S29: NMR spectra of
the synthesized compounds, Figures S30–S37: cell viability data, Figure S38, kinase inhibition data,
Figures S39–S41 and Table S1, molecular modeling data.
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